Previous close | 6.91 |
Open | 6.55 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 6.55 - 6.91 |
52-week range | 6.55 - 6.91 |
Volume | |
Avg. volume | N/A |
Market cap | 174.707M |
Beta (5Y monthly) | 1.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.64 |
Earnings date | 08 Aug 2022 - 12 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
This week we saw the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price climb by 17%. But only the myopic could...
SOUTH SAN FRANCISCO, Calif., June 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced EMA regulatory progress and tabelecleucel (tab-cel®) clinical outcomes. Data is reported from the multicenter Expanded Access Program (EAP) study in Europe for patients with relapsed or refractory (r/r) Epstein-Barr virus-dr
SOUTH SAN FRANCISCO, Calif., June 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired